Plus Therapeutics Announces Webinar to Present ReSPECT™ Glioblastoma Clinical Trial Update

AUSTIN, Texas, Nov. 13, 2020 -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing novel, personalized and targeted therapies for rare and difficult to treat cancers, today announced it will host a webinar on Thursday, November 19, 2020, 4:30 to 5:30 p.m. ET. The call will follow a poster presentation of new interim data from the ongoing National Institutes of Health-sponsored ReSPECT™ Phase 1 clinical trial evaluating the Company’s lead investigational asset, Rhenium NanoLiposome (RNL™), in patients with recurrent glioblastoma (GBM) at the 2020 Society for Neuro-Oncology (SNO) Annual Meeting. The webinar will feature a discussion of the interim safety, tolerability, dosing, feasibility and efficacy data from the ongoing ReSPECT trial. Andrew J. Brenner, M.D., Ph.D., Associate Professor of Medicine, Neurology, and Neurosurgery at The University of Texas, Health Services Center at San Antonio, will provide an update on the ReSPECT trial and provide insight on the trial data. Marc Hedrick, M.D., President and Chief Executive Officer of Plus Therapeutics, and Gregory D. Stein, M.D., M.B.A., Senior Vice President, Clinical Development of Plus Therapeutics, will discuss the technology behind RNL as well as the current treatment landscape and unmet medical need in treating patients with recurrent GBM. The sixth and final dose escalation cohort of the ReSPECT trial is underway and is expected to fully enroll by the end of 2020. In September 2020, the FDA granted both Orphan Drug designation and Fast Track designation to RNL for the treatment of patients with recurrent glioblastoma. Additional details about the ReSPECT trial are available at clinicaltrials.gov (NCT01906385). Webcast Details A live webinar with accompanying slides will be available in the Events page (http://ir.plustherapeutics.com/events) of the ‘Investors’ section of the Plus Therapeutics website or by clicking here (https://event.on24.com/wcc/r/2817882/.... Individuals can participate in an interactive Q&A session by submitting pertinent questions via the webcast platform. Please log in approximately 10 minutes prior to the scheduled start time. The archived webcast will be available in the Events section of the Company's website for 90 days. A live audio conference will be available by dialing (833) 340-0285 (toll-free) or (236) 712-2475 and entering Conference ID 6095968. Andrew J. Brenner, M.D., Ph.D. Dr. Brenner is a nationally known expert in the treatment of brain and breast cancers, with a particular research interest in developing new treatments. He has served on multiple committees and panels including for the National Institutes of Health, National Cancer Institute, Department of Defense Breast Cancer Research Program, and others. He has also served on advisory committees for a number of companies to help direct development of new drugs. His laboratory work developing new treatments has been funded by the Food and Drug Administration, National Cancer Institute, and Cancer Prevention and Research Institute of Texas. He has published nearly 50 original research articles in peer reviewed journals. Dr. Brenner is a member of the Plus Therapeutics Scientific Advisory Board. About Plus Therapeutics, Inc. Plus Therapeutics (Nasdaq: PSTV) is a clinical-stage pharmaceutical company whose radiotherapeutic portfolio is concentrated on nanoliposome-encapsulated radionuclides for several cancer targets. Central to the Company’s drug development is a unique nanotechnology platform designed to reformulate, deliver and commercialize multiple drugs targeting rare cancers and other diseases. The platform is designed to facilitate new delivery approaches and/or formulations of safe and effective, injectable drugs, potentially enhancing the safety, efficacy and convenience for patients and healthcare providers. More information may be found at PlusTherapeutics.com and ReSPECT-Trials.com. Cautionary Statement Regarding Forward-Looking Statements This press release contains certain statements that may be deemed “forward-looking statements” within the meaning of U.S. securities laws. All statements, other than statements of historical fact, that address activities, events or developments that we intend, expect, project, believe or anticipate and similar expressions or future conditional verbs such as will, should, would, could or may occur in the future are forward-looking statements.